TrialCancer2017
Phase 2 study evaluating the combination of sorafenib and temsirolimus in the treatment of radioactive iodine-refractory thyroid cancer.
Eric J Sherman et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
41 papers cite it
this paperpooled itcites it